ARCHIVES

Neratinib Graduates from I-SPY Phase II Adaptive Trial Regimen

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

NCCN Launches Outcomes Improvement Program

August 12, 2011

In Brief: Mark Kochevar Named New Administrative Officer Of DCE; Thomas Necheles Dies Suddenly at 51

September 21, 1984

Senate Confirms Elias Zerhouni For NIH Director

May 3, 2002

Animal Diagnostic Lab concept OK’d

February 18, 1994

In Brief: Bertino Moves To MSK As Head Of Chemotherapy Research; Rosemary Clive Laves ACOS For Elm

January 2, 1987

Fraumeni Appointed field Studies Chief

January 18, 1980